DCC-2618

Target: This ligand targets KIT and PDGFRA switch-control kinase regions in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for KIT and PDGFRA switch-control kinase regions. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings KIT into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated DCAF15 Degradation: DCC-2618 can be used as a ligand component in PROTAC constructs to recruit DCAF15 and drive ubiquitin-dependent degradation of an intended target. This direction supports systematic evaluation of ternary complex formation, degradation kinetics, and potency across cellular contexts to identify productive degrader configurations.

• Targeted Ubiquitination Pathway Tuning: Incorporating DCC-2618 into PROTAC designs enables researchers to modulate E3 ligase engagement and downstream ubiquitination efficiency. By varying linker length, attachment sites, and PROTAC valency, investigators can quantify changes in target ubiquitination, proteasome dependence, and degradation selectivity.

• Ternary Complex Optimization Studies: DCC-2618-based PROTACs are suitable for probing how ligand geometry influences ternary complex stability between the E3 ligase and the target protein. Researchers can apply binding and competition assays to map degradation-driving interactions, correlating complex formation with observed reductions in target abundance.

• Proteasome-Dependent Mechanism Validation: Using DCC-2618 in PROTAC workflows supports mechanistic studies confirming that target loss is mediated by the ubiquitin–proteasome system. Experimental designs can include proteasome inhibition, washout experiments, and ubiquitination profiling to distinguish degradation from transcriptional or translational effects.

• Degrader Selectivity Profiling: DCC-2618 can be leveraged to evaluate how PROTAC architecture affects off-target degradation and pathway engagement. By comparing degradation panels and dose–response behaviors across related proteins, researchers can refine ligand pairing and linker parameters to enhance specificity while maintaining robust degradation activity.

DCC-2618 is a switch-control kinase ligand scaffold that can guide KIT/PDGFR-family degrader research. Its dicarboxamide pharmacophore should remain intact during PROTAC analog design.

Structure: DCC-2618 is a switch-control kinase ligand containing a difluorophenyl amide region, a phenyl-cyclopropane dicarboxamide segment, a pyridyl ether, and an N-methylpyrazole substituent. The scaffold is conformationally organized and contains multiple amide hydrogen-bonding groups.

Reactivity: DCC-2618-derived PROTAC design should preserve the dicarboxamide and heteroaryl kinase-recognition architecture. Linker vectors may be explored from peripheral aryl, pyrazole, or pyridyl-ether regions in analogs where binding tolerance is established. Alkyl, PEG, amide, carbamate, or aryl-ether linkers may be paired with CRBN, VHL, or IAP ligands; however, controlled analog synthesis is preferred because the parent compound lacks a simple free reactive handle.